Acer Therapeutics Inc (ACER)


Stock Price Forecast

Nov. 20, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Acer Therapeutics Inc chart...

About the Company

acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica

CEO

Christopher Schelling

Exchange

OTC MARKETS

Website

https://acertx.com/

$6M

Total Revenue

41

Employees

$16M

Market Capitalization

-0.38

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ACER News

Anumana Appoints Harry S. Palmin as CFO

1mon ago, source: Business Wire

Palmin's distinguished career includes tenure as CFO at Acer Therapeutics Inc., where he played a pivotal role in the company's successful acquisition by Zevra Therapeutics, Inc. His leadership ...

Relief Therapeutics Holding SA (RLFTF)

3y ago, source: Yahoo Finance

today announced it has entered into a new exclusive definitive licensing agreement with Acer Therapeutics Inc. (Acer Therapeutics) for the development and commercialization of OLPRUVA™ (sodium ...

ACRV Acrivon Therapeutics, Inc.

2d ago, source: Seeking Alpha

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific ...

Relief Therapeutics Holding SA (RLF.SW)

20d ago, source: Yahoo Finance

today announced it has entered into a new exclusive definitive licensing agreement with Acer Therapeutics Inc. (Acer Therapeutics) for the development and commercialization of OLPRUVA™ (sodium ...

Moving iMage Technologies Stock (AMEX:MITQ), Quotes and News Summary

3mon ago, source: Benzinga.com

Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra ...

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

7h ago, source:

Century Therapeutics engages in development of genetically engineered allogeneic cell therapies for treatment of solid tumors ...

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

7d ago, source:

Company anticipates near term filing of Investigational New Drug Application to FDASOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) ...

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Nurix Therapeutics (NRIX) and Verona Pharma (VRNA)

16h ago, source: Business Insider

and Acrivon Therapeutics, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $25.33 average price target, which is a 54.6% upside from ...

Best Acer Chromebooks in 2024

1mon ago, source: Android Police

Please verify your email address. Taiwanese-American computing giant Acer has a great reputation for its affordable laptops. In particular, Acer's diverse Chromebook range offers models that span ...

Viking Therapeutics Inc.

3mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Sage Therapeutics Inc.

11mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Zevra Therapeutics Inc (ZVRA)

9d ago, source: Investing

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases,... CELEBRATION ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...